Anna Kohn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna Kohn has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Claudio Papi
Gastroenterology & Hepatology Unit, S. Filippo Neri Hospital, Rome, Italy
6 shared publications - Marco Daperno
Gastroenterology Unit, Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, Piemonte, Italy
6 shared publications Ambrogio Orlando
5 shared publications- Angelo Viscido
Department of Life, Health, and Environmental Sciences, Division of Gastroenterology, Hepatology, and Nutrition, University of L’Aquila, Piazza S. Tommasi, 1, Coppito, 67100 L’Aquila, Italy
5 shared publications Livia Biancone
Department of Internal Medicine, Gastroenterology Unit, University Tor Vergata, Rome, Italy
5 shared publications- Rita Monterubbianesi
Division of Gastroenterology, A.O. “S. Camillo-Folanini”, 00152 Rome, Italy
5 shared publications
Latest Publications
- 1 September 2017
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (9) , 997-1002
Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study
- 1 September 2017
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (9) , 997-1002
Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study
- 1 September 2014
- Published by Elsevier in Digestive and Liver Disease
- Vol. 46 (9) , 777-782
Occurrence of inflammatory bowel disease in central Italy: A study based on health information systems
- 1 September 2014
- Published by Elsevier in Digestive and Liver Disease
- Vol. 46 (9) , 777-782
Occurrence of inflammatory bowel disease in central Italy: A study based on health information systems
- 1 August 2014
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (8) , 852-858
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy
Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall colectomy-free survival and the identification of predictors of colectomy. The 3- and 12-month colectomy rates were 18.6% (95%CI 11.8%-26.9%) and 25.6% (95%CI 17.9%-34.7%) respectively. High CRP values and severe endoscopic lesions were associated with the risk of colectomy: Risk Ratio (RR)=2.15 (95%CI 1.05-4.36), and RR=5.13 (95%CI 1.55-16.96), respectively. In patients escaping early colectomy, the probability of a colectomy-free course at 12, 24, 36 and 60months was 91%, 85%, 81% and 73%, respectively. Endoscopic severity was the only predictor of long term colectomy (RR=7.0; 95%CI 1.09-44.7). Adverse events occurred in 16 patients (14%); there was one death (0.88%) due to pulmonary abscess. Infliximab is an effective and safe rescue therapy for severe corticosteroid-refractory ulcerative colitis. A three-dose induction regimen seems to be the treatment of choice for preventing early colectomy. Severe endoscopic lesions appear to be predictor of short- and long-term colectomy.
- 1 August 2014
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (8) , 852-858
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy
Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall colectomy-free survival and the identification of predictors of colectomy. The 3- and 12-month colectomy rates were 18.6% (95%CI 11.8%-26.9%) and 25.6% (95%CI 17.9%-34.7%) respectively. High CRP values and severe endoscopic lesions were associated with the risk of colectomy: Risk Ratio (RR)=2.15 (95%CI 1.05-4.36), and RR=5.13 (95%CI 1.55-16.96), respectively. In patients escaping early colectomy, the probability of a colectomy-free course at 12, 24, 36 and 60months was 91%, 85%, 81% and 73%, respectively. Endoscopic severity was the only predictor of long term colectomy (RR=7.0; 95%CI 1.09-44.7). Adverse events occurred in 16 patients (14%); there was one death (0.88%) due to pulmonary abscess. Infliximab is an effective and safe rescue therapy for severe corticosteroid-refractory ulcerative colitis. A three-dose induction regimen seems to be the treatment of choice for preventing early colectomy. Severe endoscopic lesions appear to be predictor of short- and long-term colectomy.
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Tu1144 Could Infliximab Avoid Colectomy in Patients With Severe Ulcerative Colitis? A Multicentre Italian Experience
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Tu1144 Could Infliximab Avoid Colectomy in Patients With Severe Ulcerative Colitis? A Multicentre Italian Experience
- 1 May 2012
- Published by Elsevier in Digestive and Liver Disease
- Vol. 44 (5) , 369-374
Surgical and nonsurgical hospitalization rates and charges for patients with ulcerative colitis in Italy: A 10-year cohort study
- 1 May 2012
- Published by Elsevier in Digestive and Liver Disease
- Vol. 44 (5) , 369-374
Surgical and nonsurgical hospitalization rates and charges for patients with ulcerative colitis in Italy: A 10-year cohort study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1887 Adalimumab in Active Ulcerative Colitis: A “Real-Life” Observational Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1887 Adalimumab in Active Ulcerative Colitis: A “Real-Life” Observational Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1270 Early Post-Operative Endoscopic Recurrence in Crohn's Disease Patients: Data From a Large Prospective Italian Multicenter Cohort
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1270 Early Post-Operative Endoscopic Recurrence in Crohn's Disease Patients: Data From a Large Prospective Italian Multicenter Cohort
- 1 September 2010
- Published by Elsevier in Digestive and Liver Disease
- Vol. 42 (9) , 629-634
The impact of endoscopy and specialist care on 30-day mortality among patients with acute non-variceal upper gastrointestinal hemorrhage: An Italian population-based study
- 1 September 2010
- Published by Elsevier in Digestive and Liver Disease
- Vol. 42 (9) , 629-634
The impact of endoscopy and specialist care on 30-day mortality among patients with acute non-variceal upper gastrointestinal hemorrhage: An Italian population-based study
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
W1268 The Course of Infliximab Discontinuation After Long-Term Maintenance Treatment in Crohn's Disease
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
W1268 The Course of Infliximab Discontinuation After Long-Term Maintenance Treatment in Crohn's Disease
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5) , -685-685
W1257 Infliximab for Severe Ulcerative Colitis: Short-Term and One Year Outcome of Three Dose Regimen. An Italian Multicentre Open-Label Study
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5) , -685-685
W1257 Infliximab for Severe Ulcerative Colitis: Short-Term and One Year Outcome of Three Dose Regimen. An Italian Multicentre Open-Label Study